The Benefit of #Menopausal Hormone Therapy on #Bone Density and Microarchitecture Persists After its Withdrawal

http://press.endocrine.org/doi/abs/10.1210/jc.2016-2695

MHT is associated with bone microarchitecture preservation, as assessed by TBS. The effect of MHT on TBS and BMD persists at least 2 years after withdrawal.

!!
Knee #osteoarthritis and #menopausal hormone therapy in postmenopausal women
a nationwide cross-sectional study

https://journals.lww.com/menopausejournal/Abstract/publishahead/Knee_osteoarthritis_and_menopausal_hormone_therapy.97442.aspx

The incidence of osteoarthritis (OA) increases after menopause, and may be related to hormonal changes in women. Estrogen deficiency is known to affect the development of OA, and menopausal hormone therapy (MHT) is suggested to be related to the development of OA. However, the relationship between knee OA and MHT remains controversial. The association between knee OA prevalence and MHT was investigated using large-scale national data.

Results: In the multiple logistic regression models, the OA odds ratio was 0.70 for the MHT group (95% confidence interval 0.50-0.99), compared with the non-MHT group.

Conclusions: The prevalence of knee OA was lower in participants with MHT than in those without MHT

!!
Efficacy of a standardised #acupuncture approach for women with bothersome #menopausal symptoms: a pragmatic randomised study in primary care (the ACOM study

https://bmjopen.bmj.com/content/9/1/e023637

The acupuncture intervention significantly decreased hot flushes: Δ −1.6 (95% CI −2.3 to −0.8; p<0.0001), day-and-night sweats: Δ −1.2 (95% CI −2.0 to −0.4; p=0.0056), general sweating: Δ −0.9(95% CI −1.6 to −0.2; p=0.0086), menopausal-specific sleeping problems: Δ −1.8 (95% CI −2.7 to −1.0; p<0.0001), emotional symptoms: Δ −3.4 (95% CI −5.3 to −1.4; p=0.0008), physical symptoms: Δ −1.7 (95% CI −3 to −0.4; p=0.010) and skin and hair symptoms: Δ −1.5 (95% CI −2.5 to −0.6; p=0.0021) compared with the control group at the 6-week follow-up. The pattern of decrease in hot flushes, emotional symptoms, skin and hair symptoms was already apparent 3 weeks into the study. Mild potential adverse effects were reported by four participants, but no severe adverse effects were reported.

Conclusions The standardised and brief acupuncture treatment produced a fast and clinically relevant reduction in moderate-to-severe menopausal symptoms during the six-week intervention. No severe adverse effects were reported.

!!
Cognitive behavior therapy for #menopausal symptoms (#CBT-Meno)
a randomized controlled trial

https://journals.lww.com/menopausejournal/Abstract/publishahead/Cognitive_behavior_therapy_for_menopausal_symptoms.97375.aspx

There were significantly greater improvements in CBT-Meno compared with waitlist in vasomotor symptom interference (HFRDIS; P < 0.001, η2P = 0.21) and “bothersomeness” (GCS-vm; P = 0.04, η2P = 0.06), depressive symptoms (BDI-II; P = 0.001, η2P = 0.15), sleep difficulties (PSQI; P = 0.001, η2P = 0.17), and sexual concerns (GCS-sex; P = 0.03, η2P = 0.07). These results were found even when controlling for menopausal staging and medication use. Gains were maintained at 3 months post-treatment.

Conclusions: CBT-Meno was particularly effective in improving self-reported vasomotor symptoms, depressive symptoms, sleep difficulties, and sexual concerns. Although future studies will be needed to confirm the impact of CBT-Meno on anxiety symptoms, these results suggest that this protocol is effective in targeting commonly reported menopausal symptoms.

!!
Type and timing of #menopausal #hormone therapy and #breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31709-X/fulltext

..Every MHT type, except vaginal oestrogens, was associated with excess breast cancer risks, which increased steadily with duration of use and were greater for oestrogen-progestagen than oestrogen-only preparations

Interpretation
If these associations are largely causal, then for women of average weight in developed countries, 5 years of MHT, starting at age 50 years, would increase breast cancer incidence at ages 50–69 years by about one in every 50 users of oestrogen plus daily progestagen preparations; one in every 70 users of oestrogen plus intermittent progestagen preparations; and one in every 200 users of oestrogen-only preparations. The corresponding excesses from 10 years of MHT would be about twice as great.

Association of #Menopausal Hormone Therapy With Breast #Cancer Incidence and Mortality During Long-term Follow-up of the Women’s Health Initiative Randomized Clinical Trials
https://2medical.news/2020/08/01/association-of-menopausal-hormone-therapy-with-breast-cancer-incidence-and-mortality-during-long-term-follow-up-of-the-womens-health-initiative-randomized-clinical-trials/

In the trial involving 16 608 women with a uterus, 8506 were randomized to receive 0.625 mg/d of conjugated equine estrogen (CEE) plus 2.5 mg/d of medroxyprogesterone acetate (MPA) and 8102, placebo. In the trial involving 10 739 women with prior hysterectomy, 5310 were randomized to receive 0.625 mg/d of CEE alone and 5429, placebo. The CEE-plus-MPA trial was stopped in 2002 after 5.6 years’ median intervention …

Hormone therapy as a possible solution for post #menopausal women with #nocturia results of a pilot trial
https://2medical.news/2021/03/23/hormone-therapy-as-a-possible-solution-for-post-menopausal-women-with-nocturia-results-of-a-pilot-trial/

To observe the impact of different hormonal treatment options on nocturia, its causative factors and bother in postmenopausal women. Methods: This prospective study recruited 245 postmenopausal women and divided them into four treatment groups based on patient’s choice: Estrogen + Progesterone (E+P), Estrogen-only in patients with a prior hysterectomy, tissue-selective estrogen complex (TSEC) and no treatment. Nocturia and its causative factors were observed using two …